Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia.
Rice
Lawrence
L
The Methodist Hospital, Weill Cornell Medical College, Houston, Texas, USA.
Hursting
Marcie J
MJ
Baillie
G Mark
GM
McCollum
David A
DA
D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D001120:Arginine / Q000031:analogs & derivatives; D001835:Body Weight / Q000187:drug effects*; D005260:Female; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D008297:Male; D009765:Obesity / Q000378:metabolism*; D010314:Partial Thromboplastin Time; D010875:Pipecolic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D010976:Platelet Count; D012189:Retrospective Studies; D013449:Sulfonamides; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy*; D016896:Treatment Outcome
D000925:Anticoagulants; D010875:Pipecolic Acids; D013449:Sulfonamides; D006493:Heparin; D001120:Arginine; C031942:argatroban